Certis Oncology Solutions

Certis Oncology Solutions is a non-clinical CRO that undertakes research and development for pharmaceutical and biotechnology companies. Here we survey and summarize the characteristics of the company's contract services in non-clinical studies, the pathological models it possesses, and examples of non-clinical studies.

Certis Oncology Solutions' Contract Non-clinical Trial Services Feature

Received CLIA certification

Certis Oncology Solutions is CLIA certified, a law enacted in the United States in 1988 to ensure the quality of clinical laboratories. Today, all clinical laboratories that provide laboratory services in and for the United States are required to obtain this certification.

Provides a unique platform

Certis Oncology Solution is a life science technology company,Realization of precision medicine in cancer treatmentOur goal is to provide the best possible clinical translatability. In this context, we offer a unique platform, Certis Oncology Intelligence®, that addresses the clinical translatability issues of traditional non-clinical models. models to support developers in making more accurate decisions.

Develop models for various clinical scenarios

With advances in cancer treatment, preclinical drug development is becoming more personalized and customized, making it important to select a model that can accurately reflect the objectives of the clinical trial.

In this situation, the use of custom-made cancer models for specific purposes makes the decision to continue development easier and reduces the time and effort required to search for a vast number of models. The company to address a variety of clinical scenarios, including radiation therapy, a commonly used cancer treatment worldwide,Develop custom in vitro and in vivo modelsThe company is doing so.

An example of a pathological model owned by Certis Oncology Solutions

The company has orthotopic PDX (O-PDX) models for a wide range of cancer types, including brain (GBM), breast, pancreas, lung, and sarcoma. For example, the company has expertise in surgical transplantation of HER2+ breast cancer cell lines into the brain and custom development of metastasis models that exactly replicate the metastasis from breast cancer to the brain observed in clinical practice. Thus, the company has developed brain stereotactic transplant metastasis models of HER2+ breast cancer and KRAS pathway targetingStrengths in developing custom models for drug evaluationWe have a

Certis Oncology Solutions' Non-clinical Case Studies

Evaluating therapeutic effects on tumor models

A case study on an efficacy trial evaluating the efficacy of a treatment on a specific tumor model is presented. In this example, an O-PDX model of a patient's tumor diagnosed as a muscularis species (RMS) was used to test a combination of 10 different therapeutic agents for 4 weeks in a tumor model implanted in immunocompromised mice. Results,Tumor shrinkage with 6 different treatment methodsThe most effective treatment achieved a 96.5% tumor reduction. In contrast, the no-treatment group experienced a seven-fold increase in tumor size.

Certis Oncology Solutions Company Information

Founded in 2016, Certis Oncology Solutions is a life science technology company whose mission is to enable precision medicine in cancer treatment. To provide compelling evidence of treatment effectiveness, the company offers a proprietary platform, Certis Oncology Intelligence®.